Stockwinners Market Radar for March 26, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:05 EDT Sempra Energy issues statement on European energy security - Sempra issued the following statement in response to the Joint Statement between the United States and the European Commission on European Energy Security: "We applaud today's announcement by President Biden and European Union President Von der Leyen on the establishment of a Task Force on Energy Security. Sempra stands with our European allies as they pursue their energy security and sustainability objectives, and we look forward to collaborating with the U.S. Administration to expeditiously bring more LNG to market," said Jeffrey Martin, chairman and CEO of Sempra.

17:31 EDT MindMed CFO David Guebert to retire on March 31 - Mind Medicine announced that its CFO, David Guebert, will be retiring from his position on March 31. MindMed has retained an executive search firm to assist the company's Board of Directors in identifying a new CFO with expertise and experience in the U.S. biotech market.

17:22 EDT Embecta to replace Barnes & Noble Education in S&P 600 at open on 4/4 - Becton Dickinson (BDX) is spinning off Embecta (EMBC) in a transaction expected to be completed on April 1. Post spin-off, Becton Dickinson will remain in the S&P 500. Barnes & Noble Education is no longer representative of the small-cap market space.

17:20 EDT Sonos to replace Chart Industries in S&P 600 at open on 3/30

17:19 EDT Chart Industries to replace CyrusOne in S&P 400 at open on 3/30 - Global Infrastructure Partners acquired CyrusOne in a deal that closed March 25.

16:50 EDT Two-way trading for AT&T stock expected to begin on April 4 - AT&T has been advised by the New York Stock Exchange that beginning on the trading day immediately prior to the April 5 record date for the spin-off distribution (currently April 4) and continuing through the close of trading on the business day before the closing date of the merger,1 there will be two markets in AT&T common stock on the NYSE: a "regular way" market and an "ex-distribution" market. During this period of two-way trading in AT&T common stock, there will also be a market on the Nasdaq for WBD common stock on a "when issued" basis. The trading options that will be available during the two-way trading period are: AT&T Regular Way Trading: If, during the period of two-way trading, an AT&T shareholder sells a share of AT&T common stock in the regular way market under AT&T's NYSE symbol, "T," the shareholder will be selling both the share of AT&T common stock and the right to receive shares of WBD common stock in the transaction. AT&T Ex-distribution Trading: If, during the period of two-way trading, an AT&T shareholder sells a share of AT&T common stock in the ex-distribution market under the temporary NYSE symbol "T WI," the AT&T shareholder will be selling only a share of AT&T common stock and will retain the right to receive shares of WBD common stock in the transaction. WBDWV Trading: During the two-way trading period, an AT&T shareholder also has the option of selling the right to receive shares of WBD common stock while retaining shares of AT&T common stock. This option will be available under the temporary Nasdaq symbol "WBDWV." Trades under the symbols "T WI" and "WBDWV" will settle after the closing date of the WarnerMedia-Discovery transaction. If the transaction is not completed, all trades made under these temporary symbols will be cancelled.

16:46 EDT AT&T declares Q2 dividend of 27.75c per share - With the close of the pending WarnerMedia transaction expected in April, the AT&T board of directors also declared a second quarter dividend of 27.75c per share on the company's common stock. While future dividends remain subject to board approval, this amount is consistent with AT&T's previous announcement that the board had approved an expected post-close annual common dividend of $1.11 per share. Payable on May 2 to shareholders of record of the respective shares at the close of business on April 14.

16:33 EDT Express appoints Jason Judd as CFO - Express (EXPR) announced the appointment of Jason Judd as the company's senior VP and CFO, effective April 4. Judd joins Express from Big Lots (BIG) where he served as SVP, corporate finance and treasurer since October 2019.

16:16 EDT Okta does not consider January cyber incident 'to be material' - In a regulatory filing, the company stated, "On March 21, 2022, a cybercrime group published a number of screenshots online that were taken from a computer used by a customer support engineer employed by a third-party vendor that supplies customer support services to Okta, Inc. The company has determined that the screenshots are related to an incident experienced by the vendor in January 2022. The vendor engaged a leading forensic firm to perform an investigation of the incident and has since advised the company that the incident is not ongoing and has been remediated. Based on the findings of the vendor's forensic firm, in the January 2022 incident, there was a five-day window of time between January 16-21, 2022 when the cybercrime group had access to the vendor environment, which the company also has validated with its own analysis. The company has determined that the maximum potential impact is 366 (approximately 2.5% of) customers whose Okta tenant was accessed by the vendor during the five-day window. The potential impact to the company's customers is limited to the access that the vendor support engineers have in connection with their role. These support engineers are unable to create or delete users, download customer databases, or access the company's source code repositories. Support engineers are able to facilitate the resetting of passwords and multi-factor authentication factors for users, but are unable to obtain those passwords. The company's service is fully operational. The company does not consider the incident to be material. The company continues to investigate the incident and is in ongoing communication with its customers about the incident. On March 22, 2022 and March 23, 2022, the company issued blog posts announcing details relating to the foregoing incident, and will continue to post blog updates as warranted."

15:53 EDT FDA limits use of Sotrovimab to treat COVID-19 in some U.S. regions due to BA.2 - The U.S. Food and Drug Administration is continually monitoring how authorized and approved treatments for COVID-19 are affected by changing variants-currently Omicron and the Omicron sub-variants, such as BA.2. Today, considering the most recent data available, FDA is announcing that sotrovimab is no longer authorized for use at this time in the following states and territories: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont, New Jersey, New York, Puerto Rico, and the Virgin Islands. New data included in the health care provider fact sheet shows that the authorized dose of sotrovimab is unlikely to be effective against the BA.2 sub-variant. Based on Centers for Disease Control and Prevention Nowcast data, the BA.2 sub-variant is estimated to account for more than 50% of cases in the states and territories in Regions 1 and 2 listed above as of March 19, FDA stated. Sotrovimab, sold under the brand name Xevudy, is a human neutralizing monoclonal antibody with activity against severe acute respiratory syndrome coronavirus 2, known as SARS-CoV-2, that was developed by GlaxoSmithKline (GSK) and Vir Biotechnology (VIR). Reference Link

15:24 EDT Sanofi says Libtayo now approved in Canada for fourth indication - Sanofi-aventis Canada (SNY) announced the approval of Libtayo for the treatment of adult patients with cervical cancer who have progressed on or after prior platinum-based chemotherapy and who require additional systemic therapy to treat recurrent or metastatic disease. With today's announcement, Libtayo is now approved as an immunotherapy option for four advanced cancers, the company stated. Mark Surka, Ph.D, Oncology Medical Head, Sanofi Canada, said: "While rates of cervical cancer in Canada are thankfully decliningii, due in large part to the effectiveness of the HPV vaccine in preventing cervical pre-cancers from forming, Canada still sees 1400 women diagnosed with this disease every year and who need treatment options. We're proud to have brought Libtayo to approval for the women who are diagnosed with recurrent or metastatic cervical cancer, and the healthcare professionals who treat them." Libtayo is being jointly developed by Sanofi and Regeneron (REGN) under a global collaboration agreement.

13:00 EDT Baker Hughes reports U.S. rig count up 7 to 670 rigs

12:21 EDT Wells Fargo 'welcomes' release of PAVE Action Plan - Wells Fargo & Company issued a statement regarding the Interagency Task Force on Property Appraisal and Valuation Equity, or PAVE, Action Plan issued Wednesday. "Wells Fargo welcomes the release of the PAVE Action Plan and commends the Task Force's work," said Mike Weinbach, head of Wells Fargo Consumer Lending. "Homeownership is a pillar of wealth building, and ensuring the credibility of property appraisals and valuations is of critical importance to our customers and communities. Wells Fargo has reviewed the report and has initiatives underway that support its recommendations, such as our apprenticeship program to expand the pipeline of diverse appraisers. Wells Fargo is pleased to assist in socializing and implementing the recommended initiatives to eliminate discrimination in the appraisal process and improve valuation accuracy."

12:00 EDT Didi falls -13.4% - Didi is down -13.4%, or -51c to $3.29.

12:00 EDT Enfusion falls -22.6% - Enfusion is down -22.6%, or -$3.44 to $11.79.

12:00 EDT Hoegh LNG Partners rises 20.4% - Hoegh LNG Partners is up 20.4%, or $1.12 to $6.60.

11:27 EDT Thor Industries appoints McKay Featherstone as SVP, global innovation - THOR Industries announced the hiring of McKay Featherstone, currently Airstream's VP of Product Development and Engineering, as the company's SVP of Global Innovation. Josef Hjelmaker, who currently serves as the company's Chief Innovation Officer since September of 2020, has begun transitioning his duties to Featherstone, and will provide continuous advice for a seamless transition and execution.

10:29 EDT Communications Systems' shareholders approve Pineapple Energy merger - Communications Systems announced that CSI shareholders approved Proposal #1, the proposal to approve the merger transaction with Pineapple Energy, at the reconvened special meeting of CSI shareholders that was held on March 25, 2022 at 9 a.m. CT. CSI also announced that the merger transaction with Pineapple is expected to close on Monday, March 28, 2022. Assuming that closing date: CSI shareholders of record as of the close of business on Friday, March 25, 2022 will receive one contractual non-transferable Contingent Value Right per share of CSI common stock held, which will entitle the CVR holder to a portion of the proceeds of dispositions of CSI's pre-merger assets after the effective time of the merger. CSI will change its corporate name to "Pineapple Holdings, Inc." on the closing date. Pineapple Holdings, Inc. common stock will begin to trade on the Nasdaq Capital Market under the new symbol "PEGY" as of the opening of the stock market on Tuesday, March 29, 2022.

10:17 EDT Blueprint Medicines' AYVAKYT receives EC approval for expanded indication - Blueprint Medicines Corporation announced that the European Commission has expanded the current indication for AYVAKYT to include monotherapy for the treatment of adult patients with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm or mast cell leukemia, after at least one systemic therapy. In Europe, Blueprint Medicines plans to initiate its first commercial launch in Germany following the EC approval, and the timing of AYVAKYT commercial availability will vary for other countries based on local reimbursement and access pathways. AYVAKYT will be available in 25 mg, 50 mg, 100mg and 200mg dose strengths, and the recommended starting dose in advanced SM is 200 mg once daily. The EC decision follows the positive opinion by the Committee for Medicinal Products for Human Use and is based on results from the Phase 1 EXPLORER trial and Phase 2 PATHFINDER trial, in which AYVAKYT showed durable clinical efficacy in advanced SM patients across all disease subtypes after at least one systemic therapy and a generally well-tolerated safety profile.

10:00 EDT Altus Power falls -10.4% - Altus Power is down -10.4%, or -81c to $6.99.

10:00 EDT Enfusion falls -18.1% - Enfusion is down -18.1%, or -$2.76 to $12.46.

10:00 EDT Hoegh LNG Partners rises 8.6% - Hoegh LNG Partners is up 8.6%, or 47c to $5.95.

09:55 EDT Motive Capital Corp trading resumes

09:49 EDT Motive Capital Corp trading halted, volatility trading pause

09:47 EDT Enfusion falls -12.1% - Enfusion is down -12.1%, or -$1.84 to $13.38.

09:47 EDT Hoegh LNG Partners rises 6.6% - Hoegh LNG Partners is up 6.6%, or 36c to $5.84.

09:47 EDT Joby Aviation rises 7.1% - Joby Aviation is up 7.1%, or 38c to $5.71.

09:32 EDT AST SpaceMobile, Orange enter MOU to examine SpaceMobile service in Africa - AST SpaceMobile (ASTS) announced a non-binding memorandum of understanding, or MoU, with Orange (ORAN). The joint effort would examine the opportunity for Orange to test the SpaceMobile service in one African country, following AST SpaceMobile's planned launch of BlueWalker 3, its test satellite with an aperture of 693 square feet that's designed to communicate directly with cell phones via 3GPP standard frequencies. It also paves the way for the two companies to discuss a potential agreement to serve Orange subscribers through AST SpaceMobile's planned network of BlueBird satellites.

09:12 EDT Engaged Capital reaffirms commitment to nominees for Quotient board - Engaged Capital, the beneficial owner of approximately 6.4% of the outstanding shares of Quotient Technology Iand an economic owner of approximately 9.8% of the outstanding shares, commented on the recent disclosures by the Company and reaffirmed its commitment to seeking the election of Christopher Hetrick and Matthew O'Grady to the Company's Board of Directors at QUOT's upcoming 2022 annual meeting of stockholders. Glenn Welling, Founder and Chief Investment Officer of Engaged Capital, said, "We believe that yesterday's announcement is nothing more than a defensive tactic to present stockholders with the illusion of meaningful change. In reality, all the Board has done is shuffle leadership around with the intent to further entrench incumbent directors and management. This same leadership structure has presided over QUOT's staggering underperformance and, in our view, has proven itself utterly incapable of creating any value for stockholders. The Company's Board and management team's track record is littered with a history of failures, quarter after quarter, year after year, glossed over with empty promises and a lack of accountability. We believe new blood is desperately needed inside QUOT's boardroom to prioritize stockholders' interests and yesterday's announcement does nothing to change that fact...Stockholders can easily see through the superficial 'changes' in yesterday's announcement. Apparently, a game of corporate musical chairs qualifies as 'governance enhancements' at QUOT, but the reality is that nothing has really changed. Incumbent leadership has once again shown their dedication to protecting themselves, and we are confident that other stockholders will also recognize today's announcements as simply more stockholder unfriendly actions that serve only to further entrench the incumbents, and, more specifically, ensure the continued control and influence of Steven Boal while trying to dodge a reckoning at the upcoming Annual Meeting. Accordingly, we will be moving forward with our campaign to install two new, truly independent directors to bring real change and accountability to QUOT once and for all."

09:06 EDT Galaxy Gaming secures distribution rights for Perfect Pairs - Galaxy Gaming announced that they have reached an agreement with John Wicks, creator of Perfect Pairs, to distribute Perfect Pairs Blackjack and Perfect Pairs Baccarat on land-based table games across licensed markets globally. This agreement is an expansion on Galaxy Gaming's existing partnership with John Wicks to exclusively provide Perfect Pairs live gaming progressive jackpots on land-based table games in the United Kingdom and their continued success with Perfect Pairs in the iGaming space. "We are delighted to add these beloved side bets to our content portfolio," said Todd Cravens, President and CEO of Galaxy Gaming. "Perfect Pairs is already well-loved by operators and players, so we're thrilled to enhance the game by pairing it with our progressive system and industry-leading service."

09:05 EDT DexCom announces four-for-one forward stock split - DexCom announced that its board of directors has approved a four-for-one forward split of Dexcom's common stock. The stock split is contingent upon stockholder approval of a Restated Certificate of Incorporation that would increase the number of authorized shares of common stock from 200,000,000 to 800,000,000. If stockholders approve the stock split, each share of common stock outstanding on May 19, the date of Dexcom's 2022 Annual Meeting of Stockholders, will be split into four shares of common stock. Trading is expected to begin on a split-adjusted basis on June 10.

09:03 EDT Motorsport Games partners with IndyCar driver Romain Grosjean - Motorsport Games announces that current IndyCar driver and former Formula One driver Romain Grosjean has joined the company as an advisor on its games and esports events, with particular focus on the rFactor 2 simulation platform. "In his role as a technical esports advisor for Motorsport Games, Grosjean will bring all of his racing experience together - both real-life and sim - to help develop the company's industry-leading rFactor 2 racing simulation," the company said. Throughout the year, Grosjean will participate in four technical test sessions for rFactor 2, allowing him to provide feedback and recommendations to implement to further enhance the platform. In addition to his help of iterating rFactor 2, Grosjean will also be available to advise on Motorsport Games' catalogue of esports events.

09:03 EDT Alteryx announces strategic investment in Vertis - Alteryx has announced a strategic investment in Vertis, the data-driven market intelligence platform. With Vertis, enterprises can instantly visualize and analyze their employee and real estate footprint to support critical growth and culture decisions. With this investment from Alteryx Ventures, Vertis will be better positioned to scale and meet enterprise requirements and demand in the evolving talent landscape.

09:02 EDT Nuvei announces partnership with Aircash - Nuvei announces its partnership with Aircash, "the leading Croatian mobile wallet," the company said. Nuvei will power Aircash's expansion into further European countries by providing acquiring and payment gateway services, as well as over 530 alternative payment methods. "We're excited to partner with Croatia's leading mobile wallet, enabling users to quickly and safely digitize and use their cash," said Philip Fayer, Nuvei's Chair and CEO. "Our global acquiring capabilities and comprehensive alternative payment methods will help Aircash replicate achieved success in Croatia in other Central and Eastern European countries, such as Germany, Austria and Slovenia. The Aircash wallet allows users to deposit, store and use cash in a digital form. Nuvei's solution will help Aircash to expand their pay-in and payout capabilities and enable alternative payment methods across Europe.

08:59 EDT Merck receives CHMP recommendation for Keytruda approval - Merck announced the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, has adopted an opinion recommending approval of Keytruda, Merck's anti-PD-1 therapy, in combination with chemotherapy, with or without bevacizumab for the treatment of persistent, recurrent or metastatic cervical cancer in adults whose tumors express PD-L1.

08:53 EDT Momentus completes TVAC testing on Vigoride vehicle - Momentus recently completed Thermal Vacuum Testing, or TVAC, on its Vigoride vehicle in preparation for its inaugural mission. Thermal vacuum testing allows for the simulation of space conditions, including the temperature and altitude that the Vigoride spacecraft will experience during its mission. Momentus conducted TVAC at its facility in Santa Clara, Calif.

08:47 EDT Perpetua Resources names Jessica Largent as CFO, replacing Chris Foster - Perpetua Resources (PPTA) announced that Jessica Largent will be appointed CFO, effective April 1. Largent will replace Chris Foster who has served as CFO on a contract basis since March 2021. Largent held finance leadership roles at Newmont (NEM), Turquoise Hill Resources (TRQ) and Rio Tinto (RIO) prior to joining Perpetua Resources. She has more than 15 years of mining industry experience in financial reporting, accounting, strategic planning and investor relations.

08:35 EDT Color Star Technology creates new Singapore subsidiary - Color Star Technology recently officially announced the establishment of its Singapore subsidiary, Color Metaverse Pte. The subsidiary will be fully focused on developing its business of digital commerce and products in the metaverse. This indicates that Color Star will be furthering its development into its core businesses through specialist subsidiaries.

08:34 EDT Heron Therapeutics secures pass-through payment status for ZYNRELEF from CMS - Heron Therapeutics announced that the Centers for Medicare & Medicaid Services has approved transitional pass-through status for ZYNRELEF extended-release solution, which will be established for three years beginning on April 1, 2022, for separate reimbursement outside of the surgical bundle payment in the Hospital Outpatient Department setting of care. This CMS approval makes ZYNRELEF the only local anesthetic with separate reimbursement in the hospital outpatient market. CMS grants pass-through status to certain new and innovative medical devices, drugs, and biological products. Drugs that are administered in the HOPD and Ambulatory Surgical Center settings can have pass-through and be reimbursed accordingly by Medicare. By having pass-through status, ZYNRELEF will be separately reimbursed by Medicare at Average Sales Price +6% in both the HOPD and ASC settings of care. In the ASC setting, since January 1, 2022, ZYNRELEF, under C-code C9088, has been reimbursed at ASP+6% due to recent changes in Medicare non-opioid pain management drugs and biologicals payment policies. Based on third party claims data, 72% of ZYNRELEF indicated procedures were performed in the outpatient settings in 2021, with 59% in the HOPD market and 13% in the ASC setting of care.

08:33 EDT PHI Group signs strategic cooperation agreement with Mekong Delta Group - PHI Group announced that the Company has signed a Strategic Cooperation Agreement with Mekong Delta Group, a Vietnamese company, to cooperate with each other to jointly develop, finance, and execute large-scale projects in a number of key sectors in Vietnam. According to the agreement, both parties have agreed to cooperate in the following areass: real estate: hospitality projects, residential areas, industrial projects and industrial properties, energy: solar power, wind power, biogas power, and waste-to-energy programs, environment: drinking water, waste water treatment, waste management, agriculture: hi-tech agriculture cultivation for domestic consumption and export, and finance: threshold capital, equity and debt financing. Mekong Delta Group current multi-billion U.S. dollar undertakings in Vietnam include a 300-ha urban area in Bien Hoa City, Dong Nai Province; a 1,100-ha city development project in My Duc District, Hanoi; a 500-ha renewable energy project in Binh Phuoc Province, among others. The company said, "At the same time the Company has made good progress with respect to the Asia Diamond Exchange development project, the 2,700-ha industrial and logistics zone near the new Long Thanh International Airport, Dong Nai Province, the 2,000-ha Cai Mep Ha Port project, the 3,000-ha city development project in Long Dien District, the 90-ha resort and residence project in Ho Tram, Ba Ria Vung Tau Province and the 54,000-ha sorghum growing project for Empire Spirits, Inc. in Binh Phuoc province, Vietnam. During our last trip to Vietnam we also had the opportunity to visit several key leaders of the central and local governments of Vietnam and study large-scale projects in Cu Chi District, Ho Chi Minh City. Our PHILUX Global Funds and international long-term financing programs are expected to play a major role in a number of key development projects and investment opportunities in Vietnam. On another note, both KOTA group and Five-Grain Treasure Spirits have agreed to extend the closings of these acquisitions to a later date as we continue to complete the financing for these transactions."

08:32 EDT Incyte receives CHMP recommendation for ruxolitinib - Incyte announced that the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, has issued am opinion recommending approval of ruxolitinib for the treatment of patients aged 12 years and older with acute graft-versus-host disease or chronic graft-versus-host disease, or GVHD, and who have inadequate response to corticosteroids or other systemic therapies. If approved, ruxolitinib will be the first JAK1/2 inhibitor available for patients with GVHD in Europe.

08:26 EDT Bed Bath & Beyond jumps 9% to $24.15 after cooperation pact with Ryan Cohen

08:21 EDT Novartis announces positive CHMP opinion for Kymriah for r/r follicular lymphoma - Novartis announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency adopted a positive opinion recommending the European Commission to approve Kymriah, a CAR-T cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. If approved, r/r FL would be the third indication for which Kymriah is available to patients in the European Union. Kymriah is currently approved for the treatment of pediatric and young adult patients up to and including 25 years of age with B cell acute lymphoblastic leukemia, or ALL, that is refractory, in relapse post transplant or in second or later relapse, and adult patients with r/r diffuse large B cell lymphoma, or DLBCL, after two or more lines of systemic therapy.

08:11 EDT Gamesquare Esports says Dennis Lepore joins Complexity as official creator - Gamesquare Esports and Complexity Gaming announced that Dennis "Cloakzy" Lepore, a leading Battle Royale content creator and former professional Fortnite competitor, has joined the Complexity as an official creator and part owner. The addition of Cloakzy strengthens Complexity's portfolio of talent, which includes top gaming personality Tim "TimTheTatman" Betar and expands the organization's fandom to new audiences. In partnership with Complexity and GameSquare, Cloakzy will host events, produce branded content, create limited-edition merchandise, and collaborate on unique experiences with Complexity Stars athletes and Complexity's roster of competitive players and streamers. With the addition of Cloakzy, Complexity's portfolio of talent collectively reaches over 60 million followers across social channels.

08:10 EDT Dermavant announces Phase 3 PSOARING 3 long-term extension study results - Dermavant Sciences announced Phase 3 PSOARING 3 long-term extension study results demonstrating durable improvements across efficacy outcomes, quality of life measures, and tolerability scores with investigational tapinarof cream 1% once daily for the treatment of plaque psoriasis in adults. The data, from prespecified endpoints of the Phase 3 PSOARING 3 long-term extension study, are being presented at the 2022 American Academy of Dermatology Annual Meeting, held March 25-29 in Boston. Eligible patients who completed either PSOARING 1 or 2, which were 12-week pivotal studies of tapinarof in adults with plaque psoriasis, could enroll in PSOARING 3. PSOARING 3 consisted of an additional 40 weeks of open-label intermittent treatment with tapinarof based on Physician Global Assessment score, followed by a 4-week follow-up. Patients who were randomized to tapinarof in PSOARING 1 or 2 and who also completed PSOARING 3 received tapinarof treatment for up to 52 weeks. These newly presented data include prespecified analyses of key secondary efficacy outcomes, quality of life and tolerability assessments. Importantly, continued improvements were observed in all assessments beyond the responses observed in the 12-week pivotal studies. Efficacy outcomes include changes in percentage body surface area affected and in Psoriasis Area and Severity Index, which is a measurement of the severity and extent of psoriasis. Quality of life outcomes included changes in Dermatology Life Quality Index, and tolerability assessments included both patient-reported tolerability and investigator-assessments of irritation at all sites of drug application. Investigators rated the majority of patients as having no irritation, including those who applied tapinarof to sensitive skin and intertriginous areas at all time points across 40 weeks; Long-term treatment with tapinarof cream 1% QD for up to 52 weeks demonstrated continued and durable improvement in mean PASI score, PASI75, PASI90, %BSA Affected, DLQI, and local tolerability scores. In August 2021, the U.S. Food and Drug Administration accepted a New Drug Application for tapinarof cream 1% for the treatment of plaque psoriasis in adult patients. A Prescription Drug User Fee Act target action date has been assigned in Q2 2022. If approved, tapinarof will be a potential first-in-class, novel small-molecule therapeutic aryl hydrocarbon receptor modulating agent for adults with plaque psoriasis.

08:08 EDT Entourage Health launches 'Joints for Justice' retail campaign - Entourage Health announced that its Royal City Cannabis brand recently launched 'RC Joints for Justice', a retail campaign designed to support the work of Cannabis Amnesty, an independent not-for-profit organization dedicated to remedying the harms caused by decades of cannabis prohibition. The organization pushes for equitable and evidence-based cannabis policy reform and raises awareness around inequities within the cannabis industry. The first-of-its-kind retail program centers around the sale of 3 x 0.5 gram pre-roll packages produced by Royal City, available at the Ontario Cannabis Store and participating retail outlets across the province. Proceeds of each 'RC Joints for Justice' sold, $1 per pre-roll or $3 per pack, goes directly to Cannabis Amnesty to help fund efforts that support the organization's mandate, including assisting people in navigating the pardon process and advancing social equity programs.

08:07 EDT Nuvei appoints Samir Zabaneh to board of directors - Nuvei Corporation announced it has appointed Samir Zabaneh to its Board of Directors, effective March 25, 2022. Mr. Zabaneh will also serve on the Company's Audit Committee. Zabaneh is currently the CEO and Chair of TouchBistro Inc., an all-in-one point of sale and restaurant management software provider.

08:06 EDT Stingray announces over 50 Quebec companies join initiative to help Ukrainians - More than 50 companies have expressed their interest in joining the network of Quebec businesses in support of subsistence and employment opportunities for Ukrainian immigrants, a Stingray initiative. The project aims to sponsor Ukrainian families affected by the conflict by providing individuals and families with employment and support until the situation in Ukraine stabilizes. Agropur, Aldo Group, BRP, CGI, Desgagnes, Desjardins, Exceldor Cooperative, EXFO, FX Innovation, iA Financial Group, Kruger, Lion Electric, Manac Inc. and Sagard join the existing list of Quebec companies in support of this movement. Each of these companies is prepared to join the project initiated by Eric Boyko, President, Co-Founder and CEO of Stingray, himself of Ukrainian descent, to welcome Ukrainian families to Quebec, and ensure these families are supported throughout the process. Stingray has created a network of external experts, including professionals in the domain of immigration and Human Resources to help assist participating companies in the immigration and relocation process and guide them through next steps.

08:04 EDT Morphic announces initiation of Phase 2a trial of MORF-057 in patients with UC - Morphic Therapeutic announced the initiation of MORF-057-201, the EMERALD-1 study. EMERALD-1 is a phase 2a trial of MORF-057 in patients with moderate to severe ulcerative colitis, UC. MORF-057 is a potent and selective, oral small molecule inhibitor of the alpha4beta7 integrin being studied in patients with GI disorders, initially targeting inflammatory bowel disease, IBD. "In the United States, over 1 million people are affected by IBD, a lifelong illness that can have a profound physical, emotional and social impact on patients," said Praveen Tipirneni, M.D., President and Chief Executive Officer of Morphic Therapeutic. "Each of the preclinical and clinical studies of MORF-057 to date have strongly supported the potential for MORF-057 to replicate the actions of vedolizumab, an IV-infused biologic inhibitor of alpha4beta7. MORF-057 is designed to provide an even broader group of patients with access to this proven therapeutic mechanism in pill form. With EMERALD-1 underway, we now look forward to progress in global clinical studies to advance MORF-057 as a potential new therapeutic option for people living with IBD."

08:04 EDT KWM calls for transparency from Lazydays board - Kanen Wealth Management sent a letter to the LAZY Board, which said, " We are disappointed, but not entirely surprised by your collective arrogance, in not responding to our public letter of March 21st. There remain serious governance issues at the Company that must be addressed urgently, lest shareholders lose further trust in this "Do Nothing LAZY Board." We call on the Board, and specifically Lead Independent Director and Interim CEO Bob Devincenzi, immediately to adopt a culture of transparency with its true owners, the shareholders of the Company, and take concrete steps to create shareholder value. Specifically, the Board must: publicly reveal who its Financial and Legal Advisors are, and explain why it rejected the B. Riley offer in a detailed and appropriate manner; publicly reveal its stand-alone business plan, including ROIC targets for both inorganic and organic growth opportunities, and its long-term goals with respect to number of dealerships owned; and Revenue, EBITDA and Free Cash Flow targets; discuss in detail its Capital Allocation policy and framework for returning capital via buybacks vs. growth investment; discuss its Investor Relations plan, including a potential Investor Day, the attending of Investor conferences, and increasing Wall Street research coverage; provide an update on its CEO search, and the qualities it is looking for in its next leader. Finally, in light of the continued depressed share price and significant over-capitalization, we demand the Company initiate a $100M tender for shares and warrants, which we believe would be immediately and massively accretive."

08:02 EDT Cutera receives FDA clearance for AviClear - Cutera announced the FDA's 510(k) clearance of AviClear, the first and only energy-based device to receive this designation for the treatment of mild, moderate, and severe acne.

07:40 EDT Arcutis announces results from DERMIS Phase 3 trial on roflumilast cream - Arcutis Biotherapeutics announced new pooled results from the DERMIS Phase 3 trials of roflumilast cream are available in four abstracts at the 2022 American Academy of Dermatology annual meeting. Roflumilast is a selective and highly potent phosphodiesterase-4 inhibitor being investigated by Arcutis as a non-steroidal topical treatment for multiple inflammatory skin diseases. Pooled efficacy and safety results from the DERMIS-1 and DERMIS-2 Phase 3 trials showed that at week 8, 40% of patients treated with roflumilast cream achieved IGA success - the achievement of clear or almost clear plus a greater than or equal to2 grade improvement from baseline - compared to 7% of patients with vehicle , and 48% of patients treated with roflumilast cream achieved IGA status of clear or almost clear compared to 10% of patients with vehicle. Of patients with a Worst Itch Number Rating Scale of at least 4 on a 10-point scale at baseline, 69% of patients treated with roflumilast cream achieved an improvement of four-points or more in their itch compared to 31% of patients treated with vehicle at week 8. In both trials, roflumilast cream was generally well-tolerated with a favorable safety and tolerability profile. Rates of application-site adverse events, treatment-related AEs, and discontinuations due to AEs were low and comparable with vehicle. 1% of patients discontinued the study due to an AE. The most common AEs include diarrhea, headache, insomnia, nausea, upper respiratory tract infection, application-site pain, and urinary tract infection. New post hoc analyses of pooled results from the DERMIS studies reported in two posters showed: As measured by the primary efficacy endpoint of IGA success, roflumilast cream demonstrated consistent efficacy across patients with mild, moderate, or severe psoriasis as defined by baseline body surface area, BSA. At week 8, 47% of patients with baseline BSA involvement greater than 10% achieved IGA success with roflumilast cream, compared to 2% of patients with vehicle; 37% of patients with baseline BSA of 5-10% achieved IGA success with roflumilast cream, compared to 9% with vehicle; and 40% of patients with baseline BSA involvement less than5% achieved IGA success with roflumilast cream, compared to 7% with vehicle. In patients with psoriasis plaques on their knees and/or elbows, roflumilast cream demonstrated clinically meaningful efficacy at 8 weeks, with 49% of these patients achieving IGA of clear or almost clear with roflumilast cream, compared to 8% of patients with vehicle.

07:36 EDT Oragenics receives audit opinion with going concern explanations - Oragenics announced that, as previously disclosed in its annual report on Form 10-K for the year ended December 31, 2021, which was filed on March 24 with the Securities and Exchange Commission, the audited financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the company's ability to continue as a going concern. See further discussion in footnote 1 to the company's financial statements included in the company's annual report on Form 10-K. This announcement is made pursuant to NYSE American Company Guide Section 610, which requires public announcement of the receipt of an audit opinion containing a going concern paragraph. This announcement does not represent any change or amendment to the company's financial statements or to its annual report on Form 10-K for the year ended December 31, 2021.

07:35 EDT Acasti Pharma appoints Derby to board of directors - Acasti Pharma announces that it has appointed Michael Derby to its Board of Directors. Derby brings more than two decades of experience within the biopharmaceutical industry. Having founded or co-founded seven biopharmaceutical companies, he most recently launched TardiMed Sciences.

07:34 EDT Aleafia Health provides corporate update on market share advances - Aleafia Health is pleased to provide a corporate update demonstrating that the Company continues to deliver market share advances by focusing on the highest revenue generating dried flower, pre-roll, and vape product categories. Consumers continue to express strong interest in its Sunday Market House of Brands adult-use cannabis products in these categories. "In February, the Company reported that it had changed the business' strategy towards being a branded cannabis products provider, with branded cannabis representing 80% of total net revenue in 2021 compared to 33% in 2020," said Aleafia Health CEO Tricia Symmes. "Now we continue to deliver on that strategy, with record growth in market share in February and unique product introductions that demonstrate the success of our Sunday Market House of Brands, setting the stage for future success in the highest volume cannabis categories."In February, Aleafia Health achieved record 2.06% adult use market share in four major markets, advancing 33% from 1.54% in November 2021. In the same time frame, market share in flower rose to 1.86% from 1.47%, pre-rolls rose to 2.62% from 2.09%, vapes rose to 2.18% from 0.92%, and oil rose to 4.01% from 2.68%.These advances in market share would have been stronger absent temporary capacity limitations at the Company's Grimsby greenhouse facility. Among Canadian LPs, in its four major markets, the Company ranked in February 2022: 13th overall, up from 30th in February 2021; 11th in pre-rolls, up from 37th in February 2021; 11th in vapes, up from 18th in February 2021.This 17-position overall market share rank increase, from 30th to 13th, demonstrates the success of the Sunday Market House of Brands. This growth was driven by strong retail pull-through of the Divvy product portfolio, Sunday Market's everyday brand. The Company recently shipped its first flower SKUs to British Columbia, including 14g bags of Divvy Sour Kush and Flo, and 3.5g bags of Divvy Black Widow CBD, the Company's spicy balanced flower offering. Divvy has consistently been one of the top 12 most searched brands on OCS.ca since its first product launch in April 2021. In addition, the Company's Kin Slips discrete sublingual strip brand ranks #1 in Ontario. As another indicator of consumer demand and sales momentum for adult use products, the Company for the first time has received a $1 million purchase order from Ontario, covering a wide range of products. In addition, Aleafia Health has secured purchase orders in 2022 year-to-date from Australia and Europe that exceed 2021 second half sales to international markets. Aleafia continues to target international sales as a future growth area, benefitting from its strong relationships with overseas distributors.

07:17 EDT Vaccitech announces upcoming milestones - In the second quarter of 2022, the Company expects to present additional Phase 1/2a interim efficacy data of VTP-300 in patients with chronic HBV infection at the International Liver Congress on June 22 to 26, 2022, which is also expected to be followed by Phase 1/2a full efficacy clinical trial data in the second half of this year. In the third quarter of 2022, the Company expects to initiate dosing in a Phase 1/2 clinical trial of VTP-850 in patients with prostate cancer and also expects to initiate dosing of a Phase 2 clinical trial of VTP-300 in patients with chronic HBV infection. In the fourth quarter of 2022, the Company intends to conduct an interim efficacy review of HPV001, a Phase 1/2a clinical trial of VTP-200, a potential non-invasive treatment for low grade HPV-related cervical lesions.

07:10 EDT Gamesquare Esports signs LOI for $5M credit facility - Gamesquare Esports announced that the Company has signed a letter of intent in respect of a $5M credit facility to be provided by an entity to be established by Goff Capital, Inc. and Blue & Silver Ventures, Ltd., a Jerry Jones owned company. The Credit Facility will provide the Company with additional access to capital, if required, to execute on its strategic priorities of continuing to develop profitable, cash flowing digital agencies, and a world-class content creation organization as Gamesquare businesses connect global brands with esports and gaming fans. The Credit Facility would bolster the Company's $7.7M of cash-on-hand, as of December 31, 2021. The Company expects to complete negotiations of the definitive terms of the Credit Facility and enter into a definitive agreement in respect of the Credit Facility in the coming weeks.

07:09 EDT Emerita Resources provides update on Aznalcollar legal case - Emerita Resources announces that it has been notified that Court #3 of the Seville Court will hear the final phase of the Aznalcollar criminal trial. This notification pertains to the criminal trial and is separate from the Administrative Court hearings for which the Company has not yet received notification. Magistrate Angel Marquez Romero has been appointed as the lead judge responsible for resolving the sentences that will conclude the trial. Magistrate Angel Marquez Romero has more than 40 years of judicial experience and presides over the Third Criminal Section of the Court. There will be three judges hearing this phase of the trial led by Magistrate Angel Marquez Romero. According to Emerita's external Spanish legal counsel, the hearings will likely last approximately 15-20 days given the number of people implicated and the number of charges. The date for the hearings is expected to be announced in the next few weeks and will in part be determined by when a sufficient block of time for the hearings is available in the court schedule. Upon completion of the trial, the judges will convene and draft the final resolution/decision which will conclude the trial. The criminal trial process is independent of the administrative court process. Based on correspondence received from the Administrative Court late in 2021, this court has also been deliberating for approximately six months and it is expected this process is nearing a conclusion also, although to be clear, the Company has no insights with respect to the progress or the timing of completion by the Administrative Court. The Administrative Court is the court that will deal with resolving awarding of the Aznalcollar public tender. According to Emerita's Spanish external counsel, under Spanish law if there is commission of a crime in awarding a public tender, that bid must be disqualified and the tender awarded to the next highest bidder. Emerita is the only other qualified bidder in the Aznalcollar public tender.

07:07 EDT Versus partners with Diplomat Sports to bring XEO platform to Japanese baseball - Versus Systems announced that the Company has partnered with Tokyo-based advertising agency Diplomat Sports & Entertainment to power interactive fan experiences for the Hokkaido Nippon-Ham Fighters of Nippon Professional Baseball, the highest level of professional baseball in Japan, for the league's 2022 season. Versus will activate its XEO platform's interactive arcade to enhance the in-venue experience of Japanese baseball fans each week of the 2022 season, which begins on March 25th. Versus anticipates that additional teams from Nippon Professional Baseball could activate the XEO platform throughout the course of this season. "We are proud to be partnering with Diplomat Sports & Entertainment to deliver a fun, innovative, and engaging way for Japanese baseball fans to interact with their favorite teams and enable them to win real-world rewards," said Matthew Pierce, Founder and CEO of Versus Systems. "We are excited to bring the XEO platform to Japan, working with the Hokkaido Nippon-Ham Fighters to enhance the in-game experience of their loyal fans. We look forward to bringing interactivity, engagement, and real-world prizes to sports fans attending live events across the globe."

07:07 EDT CBRE Investment Management, Altus Power to build rooftop solar projects - CBRE Investment Management (CBRE) and Altus Power (AMPS) announced plans to build and operate a portfolio of rooftop community solar projects to provide renewable energy to residential customers and CBRE IM logistics tenants in Maryland. These projects are expected to produce savings for approximately 5,700 residential customers in Maryland. CBRE IM and Altus Power each have a long-standing presence in Maryland and together are proud to bring the benefits of community solar to a broader segment of residential customers within the state. Rooftop-based solar systems of up to approximately 20MW will be located on the logistics facilities that are owned by CBRE IM's funds. Power generated from these solar systems is to be provided to both commercial tenants and residential customers. Thirty percent or more of the generated electricity is also to be allocated to low and moderate income residential customers in the state. Energy storage and electric vehicle charging may be added to these facilities in the future.

07:05 EDT ADMA announces FDA approval of extended shelf life for ASCENIV, BIVIGAM - ADMA Biologics announced the United States Food and Drug Administration's approval to extend the expiration dating from 24 to 36 months for both its ASCENIV and BIVIGAM immune globulin drug product stored at 2-8 degrees C. The expiration date extension applies to all existing ASCENIV and BIVIGAM lots currently in the commercial supply chain as well as to future production of ASCENIV and BIVIGAM in all vial sizes, production scales as well as internal and external fill-finished drug product. The newly approved 36-month dating for ASCENIV and BIVIGAM is immediately effective and product is available to U.S. healthcare providers and patients. At the present time, ADMA expects continuous and increasing supply across its IG product suite going forward.

07:04 EDT XPO Logistics sells intermodal business to STG Logistics for $710M - XPO Logistics announced that it has divested its North American intermodal business to STG Logistics, Inc. for cash proceeds of approximately $710M, subject to a customary post-closing purchase price adjustment. The intermodal unit, which XPO has reported as part of its Brokerage and Other Services segment, generated $1.2B of revenue in 2021. The divested operations provide rail brokerage and drayage services; 48 locations and approximately 700 employees have transferred to the buyer in the transaction. XPO will update its guidance to reflect the divestiture when the company reports its first quarter 2022 financial results. Raymond James & Associates, Inc. served as financial advisor to XPO for the transaction, and Wachtell, Lipton, Rosen & Katz served as legal advisor. There can be no assurance that the planned fourth quarter 2022 spin-off will occur or, if it does occur, of its terms or timing.

07:04 EDT AeroCentury completes name change to Mega Matrix - AeroCentury (ACY) announced that it has completed the company's previously announced corporate name change from "AeroCentury Corp." to "Mega Matrix Corp." In conjunction with the corporate name change, the company will begin trading on the NYSE American under the new ticker symbol, "MTMT," effective with the opening of trading on March 28.

07:03 EDT Aslan Pharmaceuticals announces anticipated upcoming milestones - Initiation of Phase 2 study of farudodstat, also known as ASLAN003, in inflammatory bowel disease is planned for the first half of 2022. Topline data from the Phase 2b TREK-AD study of eblasakimab is expected in the first half of 2023.

06:42 EDT Google files request urging judge to reject DOJ's sanction request - Google recently filed a request with Judge Amit Mehta opposing the Department of Justice, DOJ, plaintiff's motion to sanction Google and "compel disclosure of documents unjustifiably claimed by Google as attorney-client privileged." Google wrote, "Accusing an adversary of engaging in a systematic, bad-faith scheme to falsify and hide documents is a serious matter. A charge of that magnitude should be accompanied by unassailable proof. The DOJ Plaintiffs have provided none. Their allegations of sanctionable misconduct are baseless. They misread three slides from internal presentations out of the more than 4.5 million documents produced by Google to argue that Google engaged in a nefarious scheme to falsify and hide documents... Plaintiffs' alternative motion to compel seeks the same relief as their sanctions motion: blanket removal of privilege protection over large swathes of unidentified emails... Plaintiffs alternatively move to compel production of emails from Google's log "adopting the Communicate-with-Care instructions" or "created under the Communicate-with-Care rubric." For all the reasons set forth above, Plaintiffs have not proved the existence of any such bad-faith strategy. The Court should deny Plaintiffs' motion to compel for that reason alone. Plaintiffs also have not proposed any reliable mechanism for identifying such emails, nor have they tied the at-issue emails to the specific presentations they claim reflect this supposed strategy." Reference Link

06:06 EDT BRP Inc. announces return of Can-Am motorcycle with all-electric lineup - BRP announced that the Can-Am brand is returning to its motorcycle roots with a product line-up that will be completely electric. To mark the 50th anniversary of the Can-Am brand, the company will launch a family of electric 2-wheel motorcycles.

05:11 EDT DigitalBridge to acquire TowerCo from Telenet for $820M in cash - DigitalBridge announced that an affiliate, DigitalBridge Investments, has agreed to acquire the mobile telecommunications tower business of Telenet in an all-cash transaction valued at EUR 745M, or $820M, on a cash-free and debt-free basis. The transaction is being funded via a combination of debt and equity financing, including a commitment from the DigitalBridge balance sheet of EUR 470M, or $517M. DigitalBridge intends to subsequently transfer its ownership of TowerCo to a fund affiliated with DigitalBridge investment management platform, in support of the firm's continued development of new investment strategies. The transaction with Telenet will provide DigitalBridge with ownership of 100% of Telenet's passive infrastructure and tower assets, including TowerCo's nationwide footprint of 3,322 sites in Belgium, including 2,158 owned sites and 1,164 third-party sites. Through the acquisition, DigitalBridge will capitalize on the unique opportunity to create and invest in the first independent TowerCo in Belgium with an expansive footprint, a total tenancy ratio of 1.2x, and a tenancy ratio of 1.6x in towers. Under the terms of the agreement, DigitalBridge will enter into a long-term master lease agreement with Telenet, which includes an initial period of 15 years and two renewals of 10 years each. The agreement also includes a build-to-suit commitment to deploy a minimum of 475 additional new sites. The transaction is expected to close in the second quarter of 2022 and does not require any further regulatory approvals.